Free Trial

Jack Meehan Analyst Performance

Analyst at Barclays

Jack Meehan is a stock analyst at Barclays focused in the medical sector, covering 13 publicly traded companies. Over the past year, Jack Meehan has issued 1 stock ratings, including and hold recommendations. While full access to Jack Meehan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jack Meehan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
43 Last 10 Years
Buy Recommendations
44.19% 19 Buy Ratings
Companies Covered
13 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy44.2%19 ratings
Hold48.8%21 ratings
Sell7.0%3 ratings

Out of 43 total stock ratings issued by Jack Meehan at Barclays, the majority (48.8%) have been Hold recommendations, followed by 44.2% Buy and 7.0% Sell.

Exchange Coverage

ExchangePercentageCount
NYSE
69.2% of companies on NYSE
9 companies
NASDAQ
30.8% of companies on NASDAQ
4 companies

Jack Meehan, an analyst at Barclays, currently covers 13 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
92.3%
Computer and Technology
1 company
7.7%

Jack Meehan of Barclays specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

IndustryPercentage
MED INSTRUMENTS
5 companies
38.5%
MED - BIOMED/GENE
3 companies
23.1%
MEDICAL SERVICES
2 companies
15.4%
MED - OUTP/HM CRE
1 company
7.7%
MED PRODUCTS
1 company
7.7%
INSTRU - SCIENTFC
1 company
7.7%

Jack Meehan's Ratings History at Barclays

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Labcorp Holdings Inc. stock logo
LH
Labcorp
10/2/2025Boost Price Target$279.36$290.00Equal Weight
Labcorp Holdings Inc. stock logo
LH
Labcorp
2/3/2025Boost Price Target$247.81$271.00Equal Weight